Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE

Sputnik V has demonstrated 97.8% efficacy against COVID cases and 100% efficacy against severe cases of COVID in UAE

Moscow, June 29, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the data of UAE’s Ministry of Health on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign.

Efficacy among more than 81,000 subjects who had received both components of Sputnik V was 97.8%. Analysis is based on the data collected by June 8, 2021.

The Russian vaccine was also fully (100%) effective against severe cases of COVID.

Vaccination data indicates high safety of Sputnik V:

·        No severe adverse events associated with vaccination;

·        No cases of hospitalization after vaccination:

·        No deaths related to the vaccination;

·        No cerebral vein thrombosis (CVT) cases after vaccination;

·        No cases of myocarditis reported.

Sputnik V was registered in UAE in January 2021 under the emergency use authorization procedure.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:

“Sputnik V complies with the highest healthcare standards while demonstrating safety and efficacy during the vaccination in UAE. Sputnik V is one of the best COVID vaccines in the world as confirmed by data from Argentina, Serbia, San-Marino, Bahrain, Hungary, Mexico and other countries. Administering the Russian vaccine helps create durable immunity among the population and provides for lifting the restrictions and returning to normal life.”

Sputnik V has a number of key advantages:

·        The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        There are no strong allergies caused by Sputnik V.

·        The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

·        The price of Sputnik V is less than $10 per shot, making it affordable around the world.